Trial Profile

A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Gynaecological cancer; Sarcoma
Focus Therapeutic Use

Most Recent Events

18 Feb 2021 Planned initiation date changed from 1 Dec 2020 to 1 Feb 2021.
18 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as funding was withdrawn by sponsor.
06 Aug 2020 Planned End Date changed from 1 May 2027 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com